

Special Issue

Oncogenesis of Pancreatic Cancer: Where Are We

Message from the Guest Editors

Pancreatic cancer is a devastating disease with a 5-year survival rate of just 11% in the USA. It accounts for just 3% of all cancer cases but shares 7% of the total cancer-related deaths. There are several factors responsible for the high mortality of pancreatic cancer patients, such as: late detection, early metastasis, therapy resistance, and cancer-associated cachexia. In the last decade, despite the advancement of our knowledge on the pathogenesis of pancreatic cancer, much remains unexplored regarding the disease progression. A better understanding of the pathogenesis of pancreatic cancer may lead to better management of the disease, leading to improved survival of patients. The aim of the proposed Special Issue is to publish cutting-edge research articles and relevant review articles, which can help to improve our understanding of the progression of pancreatic cancer. I hope this Special Issue will be very useful for the research community and care providers.

Guest Editors

Dr. Surendra Shukla

Department of Oncology Science, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA

Dr. Tuo Hu

Department of Colorectal Surgery, The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510655, China

Deadline for manuscript submissions

closed (15 May 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/141088

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)